The fact that tideglusib has been approved by FDA and has been tested in clinical trials of Alzheimer’s Disease, Autism Spectrum Disorder and Myotonic Dystrophy renders a potential availability also for SPG11 patients. This evidence concerns the gene SPG11 and Alzheimer disease.